Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
Histopathology. 2024 Nov;85(5):804-819. doi: 10.1111/his.15302. Epub 2024 Aug 29.
The 2023 FIGO staging criteria for endometrial cancer (EC) introduced marked changes from the 2009 version. The full implication of these changes for patient diagnosis and treatment is unknown. We evaluate the differences in staging and prognostication between the two systems, with and without inclusion of molecular classification.
We assigned (1) FIGO 2009, (2) 2023 molecular-agnostic and (3) 2023 molecular-informed stages to 404 fully staged and molecularly classified patients with EC. Disease-specific and progression/relapse-free survival were analysed via the Kaplan-Meier method and compared with log-rank testing; 118 of 252 (47%) FIGO 2009 stage I patients were upstaged based on histopathological findings alone. Stage I/II subgroup survival distribution analysis showed a worse prognosis in FIGO 2023 IIB and IIC patients. In the molecular-informed FIGO 2023 system, three of 15 (20%) POLE-mutated stage I/II cases were downstaged from FIGO 2009 and eight (53%) were downstaged from molecular-agnostic FIGO 2023. Fifty-one of 60 (85%) p53-abnormal tumours were upstaged from the FIGO 2009, whereas 13 of 60 (22%) were upstaged from the 2023 molecular-agnostic stage. Molecular classification improved prognostic stratification for both 2009 and 2023 FIGO systems.
Downstaging based on POLE mutation more accurately represents patient outcomes. However, in the absence of known POLE status, applying molecular-agnostic FIGO 2023 criteria for stage I/II disease should be conducted with caution. For aggressive histotypes, additionally reporting FIGO 2009 stage should be considered. Upstaging based on substantial lymphovascular space invasion, aggressive histotype with any myometrial invasion and abnormal p53 improves prognostic discernment. Further subdivisions within stage I/II provide minimal additional prognostic information.
国际妇产科联盟(FIGO)2023 年子宫内膜癌分期标准与 2009 年版本相比有了显著变化。这些变化对患者诊断和治疗的全部影响尚不清楚。我们评估了这两个系统在不包括分子分类和包括分子分类的情况下分期和预后的差异。
我们将(1)FIGO 2009 年、(2)2023 年无分子分类和(3)2023 年有分子分类的分期标准应用于 404 例经过充分分期和分子分类的子宫内膜癌患者。通过 Kaplan-Meier 方法分析疾病特异性和进展/复发无进展生存率,并通过对数秩检验进行比较;252 例 FIGO 2009 年 I 期患者中,仅根据组织病理学发现就有 118 例被升级。I 期/II 期亚组生存分布分析显示,FIGO 2023 年 IIB 和 IIC 期患者的预后较差。在有分子分类的 FIGO 2023 系统中,15 例 POLE 突变的 I/II 期病例中有 3 例从 FIGO 2009 年降级,8 例从 2023 年无分子分类的 FIGO 降级。60 例 p53 异常肿瘤中有 51 例从 FIGO 2009 年升级,而从 2023 年无分子分类的 FIGO 升级的有 13 例。分子分类提高了 2009 年和 2023 年 FIGO 系统的预后分层。
基于 POLE 突变的降级更准确地反映了患者的结局。然而,在缺乏已知 POLE 状态的情况下,谨慎应用 2023 年无分子分类的 FIGO 标准来治疗 I/II 期疾病。对于侵袭性组织学类型,应考虑额外报告 FIGO 2009 分期。基于广泛的淋巴血管空间侵犯、任何肌层侵犯和异常 p53 的侵袭性组织学类型的升级提高了预后的辨别能力。I/II 期内的进一步细分几乎没有提供额外的预后信息。